To support a pair of colleagues' adoption of a baby boy, Christian, Merrill/Bank of America has raised more than $32,000 through their matching gifts program.
Recipients include five innovative programs from around the country that empower the CF community.
Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.
U.S. Rep. Mark Amodei of Nevada will join fellow Rep. Jim McGovern and Sens. Chuck Grassley and Ed Markey in co-chairing the Congressional Cystic Fibrosis Caucus, championing awareness of the rare disease and the Cystic Fibrosis Foundation's search for a cure.
Nearly 200 people from across the country -- including teens from 38 states -- came to Washington, D.C., on June 27 to advocate for the needs of their loved ones living with cystic fibrosis during the Cystic Fibrosis Foundation's 11th Annual Teen Advocacy Day.
Vertex Pharmaceuticals Inc. today announced that it will pursue FDA approval for the triple-combination therapy VX-445 (elexacaftor) plus tezacaftor/ivacaftor (Symdeko®).
The U.S. Food and Drug Administration has approved the use of ivacaftor (Kalydeco®) for children as young as 6 months.
The Cystic Fibrosis Foundation awarded up to $5.1 million to TB Alliance to advance a drug discovery program in partnership with Johns Hopkins University. The effort will identify compounds with the potential to treat nontuberculous mycobacteria infections that are increasingly found among people with CF.
The Cystic Fibrosis Foundation presented five outstanding members of the CF community with awards at the 2019 Volunteer Leadership Conference. These included the Tomorrow's Leader Award, the Jena Award, the Alex Award, and the Dream Big Award.
On Monday, April 1, the CF Foundation joined 16 other patient and consumer groups in filing an amicus brief supporting vital patient protections and coverage expansion included in the Affordable Care Act in the appeal of the Texas v. United States decision, which struck down the constitutionality of the health care law in 2018.